Cargando…
Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade
SIMPLE SUMMARY: Tumor cells can evade destruction via immune cells by expressing coinhibitory membrane molecules, which can suppress tumor-specific T cells. Immune checkpoint inhibitor therapies act by blocking these inhibitory pathways via monoclonal antibodies. Although this type of immunotherapy...
Autores principales: | Möller, Miriam, Turzer, Steffi, Ganchev, Georgi, Wienke, Andreas, Schütte, Wolfgang, Seliger, Barbara, Riemann, Dagmar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367406/ https://www.ncbi.nlm.nih.gov/pubmed/35954354 http://dx.doi.org/10.3390/cancers14153690 |
Ejemplares similares
-
Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy
por: Riemann, Dagmar, et al.
Publicado: (2023) -
Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade
por: Möller, Miriam, et al.
Publicado: (2020) -
Blood Immune Cells as Biomarkers in Long-Term Surviving Patients with Advanced Non-Small-Cell Lung Cancer Undergoing a Combined Immune/Chemotherapy
por: Möller, Miriam, et al.
Publicado: (2023) -
High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy
por: Riemann, Dagmar, et al.
Publicado: (2020) -
Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)